Alan List, MD and Guillermo Garcia-Manero, MD

In this segment, “Advances in MDS Treatment,” Alan List, MD and Guillermo Garcia-Manero, MD focus on new approaches and promising agents in clinical trials.

Many novel pathways and therapeutic targets are being studied, including TGF-β modulation, P53 inactivation, ALK receptor inhibitors, and immunotherapies. Promising new agents in development for MDS include luspatercept, venetoclax, CC-486, E7727 and guadecitabine.

Share this story, choose your platform!